{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T08:03:02Z","timestamp":1771401782677,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Discussion remains concerning the safety and tolerability of anti-thymocyte globulin (ATG)-based immunosuppressive therapy (IST) in older patients with aplastic anaemia (AA). Using data of 127 consecutive patients from the Dutch adult AA registry, we evaluated long-term treatment success of standard ATG-based IST as first-line treatment with a multi-state model. Only one death was potentially associated with ATG. Overall survival at 5 years was 79%. We defined Transplantation-, Treatment- and Disease-Free Survival (TT-DFS) as the ultimate success of this treatment. This means that a patient is alive, is currently transfusion-independent without having received an allogeneic stem cell transplantation, has not developed AML or MDS, and has stopped all medication for AA. The probability of TT-DFS was 42% at 5 years after start of IST. In patients younger than 40 years (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200936) and in patients aged 60 or above (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200953), this was 58% and 34%, respectively. Older age, more severe AA and absence of a PNH-clone of \u2265\u20091% all reduced the likelihood of reaching TT-DFS. These analyses on unselected nationwide data indicate that ATG-based IST is effective and safe also in older patients. They suggest that age, AA severity and presence of a PNH-clone should be taken into account when considering this treatment in older patients.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06743-5","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T04:32:04Z","timestamp":1769056324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-0045","authenticated-orcid":false,"given":"C. J. M.","family":"Halkes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8446-5133","authenticated-orcid":false,"given":"E. A. S.","family":"Koster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. J. M.","family":"Bogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-926X","authenticated-orcid":false,"given":"F. C. J. I.","family":"Heubel-Moenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9835-3223","authenticated-orcid":false,"given":"L. G. M.","family":"Daenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8847-2704","authenticated-orcid":false,"given":"S. K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M. C.","family":"Langemeijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7069-930X","authenticated-orcid":false,"given":"E.","family":"Nur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. H. G.","family":"Raaijmakers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. J. F.","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2393-715X","authenticated-orcid":false,"given":"J. M. L.","family":"Tjon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7667-9369","authenticated-orcid":false,"given":"L. C.","family":"de Wreede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"issue":"17","key":"6743_CR1","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young NS (2018) Aplastic anemia. N Engl J Med 379(17):1643\u20131656","journal-title":"N Engl J Med"},{"key":"6743_CR2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028723","author":"ES Pool","year":"2025","unstructured":"Pool ES et al (2025) Imaging mass cytometry reveals the order of events in the pathogenesis of immune-mediated aplastic anemia. Blood. https:\/\/doi.org\/10.1182\/blood.2025028723","journal-title":"Blood"},{"issue":"3","key":"6743_CR3","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.19236","volume":"204","author":"A Kulasekararaj","year":"2024","unstructured":"Kulasekararaj A et al (2024) Guidelines for the diagnosis and management of adult aplastic anaemia: A British society for haematology guideline. Br J Haematol 204(3):784\u2013804","journal-title":"Br J Haematol"},{"issue":"3","key":"6743_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjh.14372","volume":"180","author":"JM Tjon","year":"2018","unstructured":"Tjon JM et al (2018) Short-term efficacy and safety of antithymocyte Globulin treatment in elderly patients with acquired aplastic anaemia. Br J Haematol 180(3):459\u2013462","journal-title":"Br J Haematol"},{"issue":"3","key":"6743_CR5","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjh.19648","volume":"205","author":"A Prabahran","year":"2024","unstructured":"Prabahran A et al (2024) Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemia. Br J Haematol 205(3):1170\u20131179","journal-title":"Br J Haematol"},{"issue":"4","key":"6743_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ajh.27611","volume":"100","author":"B Fattizzo","year":"2025","unstructured":"Fattizzo B et al (2025) Elderly patients with aplastic anemia: treatment patterns and outcomes in the real world. Am J Hematol 100(4):584\u2013591","journal-title":"Am J Hematol"},{"issue":"4","key":"6743_CR7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood-2005-06-2485","volume":"107","author":"C Sugimori","year":"2006","unstructured":"Sugimori C et al (2006) Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 107(4):1308\u20131314","journal-title":"Blood"},{"issue":"4","key":"6743_CR8","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bjh.12661","volume":"164","author":"A Kulagin","year":"2014","unstructured":"Kulagin A et al (2014) Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study. Br J Haematol 164(4):546\u2013554","journal-title":"Br J Haematol"},{"issue":"1","key":"6743_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2109965","volume":"386","author":"R de Peffault","year":"2022","unstructured":"de Peffault R et al (2022) Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med 386(1):11\u201323","journal-title":"N Engl J Med"},{"key":"6743_CR10","first-page":"202","volume":"6","author":"C Huisman","year":"2013","unstructured":"Huisman C et al (2013) Richtlijn \u2018Diagnostiek En behandeling Van verworven aplastische anemie Bij volwassenen\u2019. Ned Tijdschr Hematol 6:202\u2013213","journal-title":"Ned Tijdschr Hematol"},{"issue":"8580","key":"6743_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(88)90388-1","volume":"1","author":"BM Camitta","year":"1988","unstructured":"Camitta BM (1988) Criteria for severe aplastic anaemia. Lancet 1(8580):303\u2013304","journal-title":"Lancet"},{"issue":"4","key":"6743_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343\u2013346","journal-title":"Control Clin Trials"},{"issue":"3","key":"6743_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/bimj.200510218","volume":"48","author":"H Putter","year":"2006","unstructured":"Putter H et al (2006) Estimation and prediction in a multi-state model for breast cancer. Biom J 48(3):366\u2013380","journal-title":"Biom J"},{"issue":"3","key":"6743_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.cmpb.2010.01.001","volume":"99","author":"LC de Wree","year":"2010","unstructured":"de Wree LC, Fiocco M, Putter H (2010) The Mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Programs Biomed 99(3):261\u2013274","journal-title":"Comput Methods Programs Biomed"},{"key":"6743_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM (2000) Modeling Survival Data: Extending the Cox Model. Springer, New York"},{"key":"6743_CR16","unstructured":"Gerds TA (2019) prodlim: Product-Limit Estimation for Censored Event History Analysis. ; Available from: https:\/\/cran.r-project.org\/package=prodlim"},{"key":"6743_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H (2016) ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, New York"},{"key":"6743_CR18","doi-asserted-by":"crossref","unstructured":"van den Brand T (2022) ggh4x: Hacks for \u2018ggplot2\u2019","DOI":"10.32614\/CRAN.package.ggh4x"},{"issue":"5","key":"6743_CR19","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3324\/haematol.2019.222562","volume":"105","author":"A Tichelli","year":"2020","unstructured":"Tichelli A et al (2020) Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a severe aplastic anemia working party trial from the European group of blood and marrow transplantation. Haematologica 105(5):1223\u20131231","journal-title":"Haematologica"},{"issue":"1","key":"6743_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood.2021012130","volume":"139","author":"BA Patel","year":"2022","unstructured":"Patel BA et al (2022) Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study. Blood 139(1):34\u201343","journal-title":"Blood"},{"issue":"23","key":"6743_CR21","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1182\/blood-2012-02-407684","volume":"119","author":"JC Marsh","year":"2012","unstructured":"Marsh JC et al (2012) Prospective study of rabbit antithymocyte Globulin and cyclosporine for aplastic anemia from the EBMT severe aplastic anaemia working party. Blood 119(23):5391\u20135396","journal-title":"Blood"},{"issue":"9","key":"6743_CR22","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3324\/haematol.2014.106542","volume":"99","author":"X Feng","year":"2014","unstructured":"Feng X et al (2014) In vivo effects of horse and rabbit antithymocyte Globulin in patients with severe aplastic anemia. Haematologica 99(9):1433\u20131440","journal-title":"Haematologica"},{"issue":"3","key":"6743_CR23","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S2352-3026(23)00395-2","volume":"11","author":"P Scheinberg","year":"2024","unstructured":"Scheinberg P et al (2024) Activity and safety of Eltrombopag in combination with cyclosporin A as first\u2013line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study. Lancet Haematol 11(3):e206\u2013e215","journal-title":"Lancet Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06743-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06743-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06743-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:03:35Z","timestamp":1771398215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06743-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6743"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06743-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional review board of the Leiden University Medical Centre approved data collection and analysis (protocol nr. C13.014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}